Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that its management team will participate in two upcoming investor conferences, providing a platform to discuss the company's business and its pipeline of therapies for central nervous system (CNS) and immunology indications.
President and Chief Executive Officer Dr. Seth Lederman will engage in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026, from 1:30 p.m. to 1:55 p.m. ET. Additionally, Lederman will hold one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16, 2026. These events offer Tonix an opportunity to connect with the investment community and provide updates on its recent progress.
The announcement comes on the heels of significant developments for Tonix, including the recent approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. This flagship medicine is a cornerstone of Tonix's CNS commercial infrastructure, which also includes acute migraine products Zembrace SymTouch and Tosymra. The company is leveraging the science behind TONMYA in Phase 2 clinical trials to explore its potential in major depressive disorder and acute stress disorder.
Beyond TONMYA, Tonix's CNS portfolio includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. In the immunology space, the company is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. These programs underscore Tonix's focus on addressing high unmet medical needs.
Participation in these conferences is critical for Tonix as it seeks to raise awareness among investors about its commercial products and late-stage pipeline. The company's recent approval of TONMYA marks a significant milestone, and the upcoming presentations will likely highlight commercial launch progress and clinical trial updates. According to the press release, the full details are available at https://ibn.fm/DKFAC, and the latest news can be found at https://ibn.fm/TNXP.
Investors and industry observers will be watching closely for any announcements regarding TONMYA's market uptake and the progress of ongoing trials. The company's ability to execute on its commercial strategy and advance its pipeline will be key factors in its long-term success.
